Vise Technologies Inc. Acquires Shares of 927 IDEXX Laboratories, Inc. $IDXX

Vise Technologies Inc. bought a new position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 927 shares of the company’s stock, valued at approximately $497,000.

Other institutional investors and hedge funds have also modified their holdings of the company. Bank of New York Mellon Corp lifted its stake in shares of IDEXX Laboratories by 156.2% in the 2nd quarter. Bank of New York Mellon Corp now owns 1,451,390 shares of the company’s stock valued at $778,439,000 after purchasing an additional 884,808 shares during the period. Price T Rowe Associates Inc. MD raised its position in IDEXX Laboratories by 71.0% during the first quarter. Price T Rowe Associates Inc. MD now owns 1,988,912 shares of the company’s stock worth $835,244,000 after acquiring an additional 825,965 shares during the period. Generation Investment Management LLP acquired a new position in shares of IDEXX Laboratories during the 2nd quarter worth about $304,277,000. Select Equity Group L.P. acquired a new stake in IDEXX Laboratories in the 1st quarter worth about $194,834,000. Finally, Nuveen LLC purchased a new stake in IDEXX Laboratories during the 1st quarter worth approximately $179,784,000. Institutional investors and hedge funds own 87.84% of the company’s stock.

Insiders Place Their Bets

In related news, EVP Nimrata Hunt sold 9,425 shares of the business’s stock in a transaction that occurred on Friday, November 7th. The stock was sold at an average price of $703.34, for a total transaction of $6,628,979.50. Following the completion of the sale, the executive vice president owned 21,149 shares in the company, valued at $14,874,937.66. The trade was a 30.83% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director M Anne Szostak sold 2,187 shares of the company’s stock in a transaction on Friday, August 22nd. The shares were sold at an average price of $647.33, for a total transaction of $1,415,710.71. Following the completion of the transaction, the director owned 262 shares of the company’s stock, valued at approximately $169,600.46. The trade was a 89.30% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders own 0.98% of the company’s stock.

Analysts Set New Price Targets

A number of analysts have commented on IDXX shares. Piper Sandler reiterated a “neutral” rating and issued a $700.00 price objective (up previously from $510.00) on shares of IDEXX Laboratories in a report on Monday, August 11th. JPMorgan Chase & Co. boosted their target price on shares of IDEXX Laboratories from $675.00 to $775.00 and gave the company an “overweight” rating in a report on Tuesday, November 4th. Jefferies Financial Group restated a “buy” rating and set a $830.00 price target on shares of IDEXX Laboratories in a report on Tuesday, November 4th. UBS Group lifted their target price on IDEXX Laboratories from $710.00 to $750.00 and gave the company a “neutral” rating in a research report on Tuesday, November 4th. Finally, Weiss Ratings lowered shares of IDEXX Laboratories from a “buy (b-)” rating to a “hold (c+)” rating in a report on Thursday. One research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and four have assigned a Hold rating to the company’s stock. According to MarketBeat.com, IDEXX Laboratories has a consensus rating of “Moderate Buy” and an average price target of $730.50.

IDEXX Laboratories Stock Performance

NASDAQ:IDXX opened at $689.93 on Friday. IDEXX Laboratories, Inc. has a 52 week low of $356.14 and a 52 week high of $735.00. The company has a fifty day simple moving average of $651.74 and a two-hundred day simple moving average of $587.72. The company has a quick ratio of 0.79, a current ratio of 1.11 and a debt-to-equity ratio of 0.31. The company has a market cap of $55.09 billion, a price-to-earnings ratio of 57.45, a price-to-earnings-growth ratio of 4.06 and a beta of 1.62.

IDEXX Laboratories (NASDAQ:IDXX) last released its earnings results on Monday, November 3rd. The company reported $3.22 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.14 by $0.08. The firm had revenue of $1.11 billion during the quarter, compared to analyst estimates of $1.07 billion. IDEXX Laboratories had a return on equity of 64.42% and a net margin of 24.41%.IDEXX Laboratories’s revenue was up 13.3% compared to the same quarter last year. During the same period last year, the business posted $2.80 earnings per share. IDEXX Laboratories has set its FY 2025 guidance at 12.810-13.010 EPS. As a group, equities analysts anticipate that IDEXX Laboratories, Inc. will post 11.93 earnings per share for the current fiscal year.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.